Аutosomal recessive limb-girdle muscular dystrophy type 2A: two cases in Ukraine with different age of onset
DOI:
https://doi.org/10.26641/2307-0404.2021.3.242343Keywords:
limb-girdle muscular dystrophy, CAPN3 gene, Gower’s sign, proximal muscle weaknessAbstract
The paper reports on two cases of young women from Ukraine with autosomal recessive limb-girdle muscular dystrophy type 2A with different age of symptoms onset and an absence of any family history presented with gradual onset of proximal muscle weakness in four limbs and thinning of shoulders, arms and thighs. Both patients had elevated creatine phosphokinase level and c.550delA mutations in CAPN3 gene. Sequence analysis and deletion/duplication testing of the 159 genes from skeletal muscles disease testing panel of 5-year-old girl identified deletion of exon 8 (heterozygous) and c.550delA (p.Thr184Argfs*36) mutation (heterozygous), were in CAPN3 gene. Magnetic Resonance Imaging of soft tissue of the proximal lower extremities was performed which showed signs of symmetrical atrophic changes in the major adductor muscle, the long and short adductor muscles, the semitendinosus muscle of the thigh, as a manifestations of autosomal recessive limb-girdle muscular dystrophy type 2A. Homozygous, pathogenic variant of the defect in the CAPN3 gene c.550del (p.Thr184Argfs * 36) was identified in a 25-year-old woman. Type 2A is the most common form of limb-girdle muscular dystrophy, accounting for about 30% of cases. The autosomal recessive limb-girdle muscular dystrophy type 2A is on caused by mutations in the CAPN3 gene, and it is characterized by selective atrophy and weakness of proximal limb and girdle muscles. The age of onset of muscle weakness is extremely variable; the most common being between 8 and 15 years, although it can range between 2 and 50 years. The diagnosis can be suspected by findings on a muscle biopsy or when a doctor experienced in muscular dystrophy examines you. A serum creatine kinase blood test may also show raised levels which indicate a problem in the muscles. The diagnosis has to be confirmed by means of identifying a mutation in the CAPN3 gene which is done on a deoxyribonucleic acid sample from a blood test. To date there are no specific treatments for limb-girdle muscular dystrophy, however careful management of the symptoms of the condition can improve a person’s quality of life. Joint contractures (tightening) can occur in limb-girdle muscular dystrophy and therefore regular physiotherapy is recommended.
References
Albuquerque M. Limb-girdle muscular dystrophy in Brazilian children: clinical, histological and molecular characterization. Arquivos de Neuro-Psi¬quiatria. 2014;72(6):481-481
doi: https://doi.org/10.1590/0004-282x20140037
Cotta A, Carvalho E, da-Cunha-Júnior A, Paim J, Navarro M, Valicek J, et al. Common recessive limb girdle muscular dystrophies differential diagnosis: why and how?. ArquivosdeNeuro-Psiquiatria. 2014;72(9):721-734. doi: https://doi.org/10.1590/0004-282X20140110
Dincer P. A cross section of autosomal recessive limb-girdle muscular dystrophies in 38 families. Journal of Medical Genetics. 2000;37(5):361-367. doi: https://doi.org/10.1136/jmg.37.5.361
Liu W, Pajusalu S, Lake N, Zhou G, Ioannidis N, Mittal P et al. Estimating prevalence for limb-girdle mus¬cular dystrophy basedon public sequencing databases. Genetics in Medicine. 2019;21(11):2512-2520. doi: https://doi.org/10.1038/s41436-019-0544-8
Grimm D, Hanisch F, Liu X, Müller-Reible C, Zierz S, Deschauer M. Frequency of calpain-3 c.550delA mutation in limb girdle muscular dystrophy type 2 and isolated hyperCKemia in German patients. Aktuelle Neurologie. 2006;33(S 1).
doi: https://doi.org/10.1055/s-2006-95302211
Haberlová J. Evaluation and Treatment of Myopathies. European Journal of Human Genetics. 2015;23(10):1433-1433. doi: https://doi.org/10.1038/ejhg.2015.127
Kaplan J, Hamroun D. The 2015 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscular Disorders. 2014;24(12):1123-1153. doi: https://doi.org/10.1016/j.nmd.2014.11.001
Khadilkar S. Limb girdle muscular dystrophies in India. Neurology India. 2015;63(4):495. doi: https://doi.org/10.4103/0028-3886.161989
Broglio L, Tentorio M, Cotelli M, Mancuso M, Vielmi V, Gregorelli V, et al. Limb-Girdle Muscular Dystrophy-Associated Protein Diseases. The Neurologist. 2010;16(6):340-352. doi: https://doi.org/10.1097/NRL.0b013e3181d35b39
Wang C, Liang W, Minami N, Nishino I, Jong Y. Limb-girdle Muscular Dystrophy Type 2A with Mutation in CAPN3: The First Report in Taiwan. Pediatrics & Neonatology. 2015;56(1):62-65. doi: https://doi.org/10.1016/j.pedneo.2013.01.018
Oliveira Santos M, Ninitas P, Conceição I. Severe limb-girdle muscular dystrophy 2A in two young siblings from Guinea-Bissau associated with a novel null homozygous mutation in CAPN3 gene. Neuromuscular Disorders. 2018;28(12):1003-1005. doi: https://doi.org/10.1016/j.nmd.2018.09.009
Pegoraro E, Hoffman EP. Limb-Girdle Muscular Dystrophy Overview. 2000 Jun 8 [Updated 2012 Aug 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1408/
Stöllberger C, Finsterer J. Cardiopulmonary involvement in limb girdle muscular dystrophy 2A. Muscle & Nerve. 2017;56(4):E38-E38. doi: https://doi.org/10.1002/mus.25369
Angelini C, Nardetto L, Borsato C, Padoan R, Fanin M, Nascimbeni A, et al. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurological Research. 2010;32(1):41-46. doi: https://doi.org/10.1179/174313209X380847
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
